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Globally, tobacco consumption continues to cause a huge burden of preventable diseases.
Chile has been leading the tobacco burden ranking in the Latin American region for the last
ten years; it has currently a 33. 3% prevalence of current smokers.
Methods
A microsimulation economic model was developed within the framework of a multi-country
project in order to estimate the burden attributable to smoking in terms of morbidity, mortal-
ity, disability-adjusted life-years (DALYs), and direct costs of care. We also modelled the
impact of increasing cigarettes’ taxes on this burden.
Results
In Chile, 16,472 deaths were attributable to smoking in 2017, which represent around 16%
of all deaths. This burden corresponds to 416,445 DALYs per year. The country’s health
system spends 1.15 trillion pesos annually (in Dec 2017 CLP, approx. U$D 1.8 billion) in
health care treatment of illnesses caused by smoking. If the price of tobacco cigarettes was
to be raised by 50%, around 13,665 deaths and 360,476 DALYs from smoking-attributable
diseases would be averted in 10 years, with subsequent savings on health care costs, and
increased tax revenue collection. In Chile, the tobacco tax collection does not fully cover the
direct healthcare costs attributed to smoking.
Conclusion
Despite a reduction observed on smoking prevalence between 2010 (40.6%) and 2017
(33.3%), this study shows that the burden of disease, and the economic toll due to smoking,
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remain high. As we demonstrate, a rise in the price of cigarettes could lead to a significant
reduction of this burden, averting deaths and disability, and reducing healthcare spending.
Introduction
In 2017, 7.1 million deaths and 182 million disability-adjusted life-years (DALYs) were attrib-
uted globally to tobacco [1]. Well above the global average of 25% prevalence for current
smoking, Chile continues leading with the highest prevalence of smoking in Latin America, at
33.3% in 2017 (38% in men and 29% in women) [2]. Prevalence is high despite the reduction
observed in the 2017 National Health Survey (NHS) in comparison to the 2010 and the 2003
NHS. In the latter, adult prevalence peaked at 43.5%. Likewise, according to the Global Youth
Tobacco Survey (GYTS)–in which Chile was included for the first time in 2000 –the country
has continued to show high rates of adolescent smoking, with an important feminization phe-
nomenon where adolescent female consumption is higher than consumption in adolescent
males [3].
Chile initiated a public policy against tobacco consumption with the subscription to the
2003 World Health Organization (WHO) Framework Convention on Tobacco Control
(FCTC) [4], which was ratified by the country in 2005. In 2008, the Chilean Ministry of Health
(MoH) estimated through its Burden of Disease study [5] that one out of eleven deaths were
directly attributable to smoking. In addition, they reported 61,093 DALYs: 37,976 due to dis-
ability and 23,117 due to premature death [5]. In 2010, a cost-effectiveness study, also man-
dated by the MoH [6], reported that smoking-cessation interventions (e.g. individual/group
counseling, and nicotine replacement therapy), were very cost-effective, with an incremental
cost-effectiveness ratio (ICER) of less than one Gross Domestic Product (GDP) per capita per
DALY avoided. However, there was considerable uncertainty associated with the effectiveness
data available at that time.
The legislative road map in the fight against tobacco began in Chile in 2006 with amend-
ments [7] to National Law 19,419 [8], which regulates tobacco-related activities. The first mod-
ifications to the law aimed at gradually implementing smoke-free areas and banning
advertising. Since 2013, through Law 20,660 [9], advertising tobacco products is totally prohib-
ited, as well as smoking in enclosed spaces. The structure of cigarette taxes was also modified,
by increasing the specific component of the excise tax. These changes also led to the prohibi-
tion of the promotion and sponsorship of tobacco, both directly and indirectly.
According to the MPOWER strategy promoted by WHO in the context of the FCTC, Chile
has progressed favorably in four out of the five areas of action that this policy package defines,
lagging behind only in the action involving “offering help to quit tobacco use” [10]. Regarding
taxation, in 2016 taxes accounted for more than 75% of the final price of the most sold cigarette
pack [3, 11], reaching 82.5% in 2019 [10]. According to WHO, since 2017 Chile stands out as
one of the 33 countries to fulfill the taxes prerogative [12]. However, the final price of a ciga-
rette packet (around $4 US dollars) remains affordable for most Chileans and, therefore, there
is still room for higher price increases with a double potential impact of curtailing demand
and increasing tax collection. There is recent national evidence that household tobacco expen-
diture displaces disposable income for health care as well as for education [13]. Therefore,
efforts to reduce tobacco consumption should also encompass treatment for highly dependent
individuals. In this regard, several Pan American Health Organization (PAHO) and WHO
reports [3, 10, 12] highlight that treatment of smoking dependence in primary health care,
PLOS ONE The burden of smoking in Chile
PLOS ONE | https://doi.org/10.1371/journal.pone.0237967 August 28, 2020 2 / 16
Funding: The International Development Research
Center of Canada (IDRC) provided funding for this
study in the form of a grant awarded to APR for the
project "Empowering health care decision makers
to achieve regional needs for tobacco control in
Latin America" (107978-001). The funder had no
role in study design, data collection and analysis,
decision to publish, or preparation of the
manuscript.
Competing interests: The authors have declared
that no competing interests exist.
community services or hospitals, is not yet available in Chile. Although in some private prac-
tices smoking cessation therapies are prescribed, these are not covered or reimbursed by the
health care system.
Increasing tobacco taxes has been considered the most effective way to reduce consumption
[14, 15]. Higher tobacco taxes raise the price of a cigarette pack, prompting individuals to
reducing its demand in line with the “price elasticity”. A national study on price-elasticity
revealed a value of -0.45, implying that a 10% price increase in a pack of cigarettes would lead
to a 4.5% decline in the demand [16]. Chile has a mixed tobacco tax structure, with a fix 30%
ad valorem tax and a specific tax of 0.0010304240 unidades tributarias mensuales (UTM) per
unit of cigarette in the package (approx. U$D 0.07). UTM is a unit of account used in Chile for
tax and fines purposes, updated monthly according to inflation. In Chile the value added tax
(VAT) is 19%, which is estimated on top of manufacturing costs plus specific taxes. The rela-
tive importance of these taxes changed in 2013, when the specific tax suffered an increase in
relation to the ad valorem tax. However, to date there is not a minimum price policy, and price
dispersion (that is, cheapest brand price divided by premium brand price × 100) reaches 58%,
which is low, and thus provides opportunities for brand substitution [10]. Therefore, although
modifications to the tax regimen had an impact on increasing the final price of the cigarettes
pack, they seem insufficient, and further price increases should make cigarettes less affordable
in Chile. Tax increases should target the specific tax component, which does not depend on
the manufacturing cost, thus limiting the tactics manufacturers employ to reduce the produc-
tion costs in order to minimize the tax burden.
The extent to which current control policies for tobacco control in Chile have been paying
off, as well as the potential to deepen implementation, are important questions for policymak-
ing. The present study is part of a collaborative research coordinated by the Department of
Evaluation of Health Technologies and Health Economics of the Institute of Clinical and
Healthcare Effectiveness (IECS) of Argentina. A team of more than 40 researchers and health
decision makers from universities, research centers, and public institutions in Argentina,
Bolivia, Brazil, Chile, Colombia, Costa Rica, Ecuador, Honduras, Mexico, Paraguay, Peru, and
Uruguay conducted the broader project.
Aggregated results are available for the region [17], as well as for some specific countries
such as Argentina [18], Perú [19], Paraguay [20], and Brazil [21]. For Chile, this initiative rep-
resents the first attempt to quantify the economic cost of smoking-attributable diseases using
country-specific data. The application of the model to the Chilean population was first pub-
lished in 2014 as grey literature [22], where data corresponded mostly to the year 2010. Here,
we present an updated analysis based on the most recent information regarding smoking prev-
alence [2], tobacco-related mortality (for 2016), and population structure from the 2017 census
[23]. However, we refer to the previous results for comparison purposes, when this seems rele-
vant from a policy-evaluation perspective.
In this paper, our objective is twofold: to report the tobacco-related burden on disease,
mortality and direct medical costs for Chile, and to estimate the health and financial impact of
different levels of cigarettes price increase through increasing tobacco excise taxation.
Methods
Model development
A mathematical model was used to estimate the probabilities of people becoming ill or dying
for each of the conditions associated with smoking. The detailed description of the model, as
well as its calibration process, can be found in another study [24]. The model, programmed in
Excel (Microsoft1Office Excel Professional Edition 2003) with Macros in Visual Basic
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(Microsoft Visual Basic1 6.3), corresponds to a first order Monte Carlo simulation, which
carries out the analysis of a hypothetical cohort, along a discrete time period.
This model uses a prevalence-based approach to simulate a static cohort for one year. How-
ever, to estimate disease incidence, quality of life, health outcomes and healthcare costs for
each sex and age strata in Chile for smokers, ex-smokers and never smokers we used the
microsimulation model. In this way, we obtain aggregated population health outcomes and
direct healthcare costs. In this cross-sectional approach all individuals by age and sex are con-
sidered, and smoking-related events are estimated through specific disease equations, which
incorporate epidemiological and demographic data derived from the evidence and national
healthcare statistics.
The health conditions analyzed were: coronary and non-coronary heart disease; cerebrovas-
cular disease; chronic obstructive pulmonary disease (COPD); pneumonia; lung, mouth, lar-
ynx, pharynx, esophagus, stomach, pancreas, kidney, bladder and cervix cancer; and leukemia.
The model allows cohort follow-up according to age and sex, based on the annual risk of
occurrence of the events and according to whether individuals are smokers, never-smokers or
ex-smokers. We considered a cohort of people of 35 years of age and older living in Chile in
2017. We used probabilities that reflect the risk of occurrence of acute and chronic events
based on the relative risks (RR) of never-smokers (baseline incidence) against those of smok-
ing status. Risk of death was defined according to the events and conditions that individuals
suffered, including general mortality (by sex and age). Finally, using previously determined
parameters of quality of life and unit costs, we estimated the costs and quality-adjusted life-
years (QALYs) for the overall survival time of the cohort.
The study used the DALY approach to decompose years of life lost due to premature mor-
tality (YLL) and years lost due to disability (YLD). However, DALYs were not age-weighted,
and for the base-case scenario values, they were not discounted either.
To estimate YLD, we used utility values identified through an extensive literature searching,
where disability weights equal 1 –utility, while YLL were derived from Chilean life tables.
An analysis of the differences in events, deaths, and associated costs was conducted, in
order to quantify the smoking-attributable disease burden. We did this initially by simulating
a hypothetical Chilean cohort without smokers or ex-smokers, and then by running a cohort
to which the prevalence of smokers and ex-smokers were incorporated. The evaluation plat-
form allows for the simulation of the effect of different strategies aimed at preventing and con-
trolling tobacco consumption, such as increasing cigarette taxes. The model was validated and
used to estimate the burden of disease attributable to smoking and the potential impact of dif-
ferent interventions [17–21, 25].
We explored three scenarios for price increase assuming policies for cigarette tax increase
that resulted in generating 25%, 50% and 75% total price increase. The effect of these price
increases on the prevalence of smoking was calculated as:
Prevalence ¼ PrevBþ ðEd � DP � Ir � PrevBÞ
Where PrevB is the baseline prevalence of smoking before price increase; Ed is the price
elasticity of demand (-0.45); ΔP is the per cent price variation for each scenario (25%, 50% or
75%); and Ip is the proportion of the variation on cigarette consumption expected to impact
on smoking prevalence. Ip was assumed to range from 0.11 for a 25% price increase to a maxi-
mum of 0.34 for a 75% price increase. The reduction in prevalence assumedly affects all ages
and to both sexes proportionally. The model assumes that smokers who quit become ex-smok-
ers in the first two scenarios, while only in the third scenario do some ex-smokers adopt a risk
similar to that of never-smokers.
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Data sources
Regarding epidemiological data, local sources of good quality were the first choice; when not
available, we used international sources as a second option provided we could consider them
‘transferable’. Thirdly, if none of the previous options were available, an estimate was derived
based on the best available data for the country. The probability of acute events, the incidence of
chronic diseases and its progression, as well as mortality rates associated with the conditions
analyzed for each age and sex group, were drawn mainly by combining estimations from the
Global Burden of Cancer (Globocan) for Chile, and MoH’s Department Statistics and Informa-
tion on Health (DEIS). For COPD and some types of cancer, corrections were made for under-
registration of cases and deaths. Taking into consideration ill-defined deaths, projections were
modelled with the best estimates, but these were contrasted with the national registry for stroke
and acute myocardial infarction (AMI). Epidemiological parameters for lung cancer were cali-
brated through a Markov model considering country-specific data on diagnosis and survival.
Since the model does not assess the consequences of passive smoking directly, the estimate
of deaths, years of life lost, and costs associated with passive smoking was incorporated using
approximations made in studies from the US, which can be considered conservative, since the
US has been implementing smoking regulation long before Chile. Indeed, an additional bur-
den of 13.6% in men and 12% in women over direct estimations was applied, based on studies
of the U.S. Department of Health and Human Services [26]. Table 1 shows an overview of the
main input parameters and its sources, grouped by type.
Treatment cost estimates
The costing methodology combined micro and macro costing techniques. The direct costs of
treatment of the 17 conditions analyzed are presented in annual costs for chronic diseases, and




Demographics • Population structure: adults 35–100 years of age • Chile 2017 Census [23]
Epidemiology • Smoking prevalence (by sex and age group) • 2016–2017 National Health Survey [2]
Epidemiology • Mortality due to acute and chronic conditions (by sex and age
group)
• 2016 Deaths registry (DEIS) Health statistics—Ministry of Health [28]
• p>Globocan [22]
Epidemiology • Incidence, prevalence, and hospital care of acute and chronic
conditions
• Systematic Review [27]
• Health statistics—Ministry of Health [28]
• Use of specific equations • Globocan [22]
Epidemiology • Relative risks of mortality for smokers, ex-smokers, and never-
smokers
• Cancer prevention study II. U.S. Department of Health and
Human Services
[26]
Epidemiology • Passive smoking • Cancer prevention study II. U.S. Department of Health and
Human Services
[26]
Economics • Treatment costs for annual and acute events of conditions • AUGE Study of verification of the mean individual cost per
beneficiary
[29]
• Empirical study of costs in the public sector by FONASA [30]
• Delphi exercise with clinical experts done in Argentina [18]
• Chilean cost-effectiveness study [6]
Utilities • Several international sources reporting utilities in a 0–1 scale for
the construction of QALYs




Economics • Tobacco, cigars, and cigarettes tax collection • 2017 Financial Treasury Report prepared by the General
Treasury of the Republic of Chile
[31]
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as per event for acute conditions. In Chile, the national program of explicit guarantees in
health (called AUGE) provides cost estimates for legally granted services. The study of ‘verifi-
cation of the mean expected cost per beneficiary’ (EVC) corresponds to a detailed micro-cost-
ing exercise for each of the diseases guaranteed, and considers the stages of diagnosis,
treatment, and follow-up. These estimations weigh the cost of treatment in the public and pri-
vate sector, according to population affiliation. In Chile, nearly 75% of the population is affili-
ated to the national health fund (FONASA) while around 15% is affiliated to the ISAPRES
(private insurers). The remaining 10% comprises other institutional arrangements for health-
care, including a low proportion corresponding to the uninsured population.
Since AUGE is a mandatory program covering both subsystems, private and public costs
were weighted in the calculation. We applied a general weighting of 70% public and 30% pri-
vate to obtain mean annual costs, however there were some adjustments to this weighting for
services provided mainly for the private sector or conversely for the public system [22]. We
prioritized the EVC as the main source of costing for pathologies covered through AUGE.
Consequently, some costs were obtained from the EVC study [29]; however, we made adjust-
ments in most cases to correct for the underestimation of public unit costs. To do this, we used
an empirical health care service costing study for the public sector, commissioned by FONASA
[30]. As AUGE does not cover all conditions involved in this study, we estimated the cost of
some treatments from scratch, or based on other studies. The cost of lung cancer (not covered
in AUGE before 2019) was taken from the national cost-effectiveness study that had consid-
ered this condition among others [6]. The cost for other cancers was estimated using relative
proportions in costs obtained from an Argentinian study [18]. In this study, a Delphi exercise
with local clinical experts was implemented, based on the cost of treating lung cancer, which
was obtained by micro-macro costing. The experts estimated the likely proportion of some less
frequent types of cancer in relation to lung cancer. All monetary values were in Chilean pesos
(CLP) from December 2017 and were also converted to US dollars (U$D), using the mean
observed exchange rate published by the Chilean Central Bank for 2017 (1 U$D = 649.33
CLP).
Results
We completed the search and selection of all parameters needed to populate the model. A sum-
mary of the smoking prevalence in Chile for the age groups of interest is shown in Table 2,
while “S1 Table” shows the prevalence and population, for single age (35 years to 100) and sex.
The direct costs of treating the conditions studied in the Chilean healthcare systems are
shown in Table 3, while the utility values assigned to each condition are presented in Table 4.
Relative risks for smokers and ex-smokers in reference to never-smokers, which, as
explained earlier, were taken from the Cancer prevention study II [26], are contained in the S2
Table, where we provide a detail by tobacco-related condition and sex.
Table 2. Smoking prevalence by age range, sex and smoking status (National Health Survey 2017).
Males prevalence Females prevalence
Age group Smokers Ex- smokers Smokers Ex- smokers
35–44 49,51% 23,59% 35,72% 23,61%
44–65 31,30% 36,78% 29,84% 23,67%
> = 65 15,69% 45,68% 9,05% 32,65%
https://doi.org/10.1371/journal.pone.0237967.t002
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Mortality, morbidity, and costs of smoking
In Chile, we estimate 16,742 deaths attributable to smoking annually, a number that represents
around 39% of deaths from smoking-related diseases (43,322) and about 16% of all cases of
death. Among the diseases analyzed, nearly 180,000 events are expected each year, of which
85,000 (47%) are attributable to cigarette consumption. In terms of costs, these conditions bur-
den the Chilean healthcare system with nearly U$D 3.4 billion, of which U$D 1.8 billion (52%)
are smoking-attributable treatment costs. We show the main results drawn from modeling the
burden attributable to cigarettes consumption in Table 5.
Chronic obstructive pulmonary disease (COPD) represents the top cause of smoking-
attributable mortality (30.1%), followed by lung cancer (18.4%), passive smoking (11.5%),
acute myocardial infarction (7.8%), stroke (5.5%), and cardiovascular deaths of non-ischemic
cause (5.5%). When aggregating by disease group, COPD (30.1%) and lung cancer (18.4%) are
Table 3. Direct medical costs estimated in CLP of December 2017 and U$D�.
Disease events (annual) Cost CLP Cost U$D Method/source
Acute myocardial infarction (AMI) 3,015,985 4,645 AUGE- FONASA study
Non-AMI ischemic event 2,065,883 3,182 AUGE–FONASA study
CHD follow-up (annual) 1,104,263 1,701 AUGE–FONASA study—Delphi
Stroke 3,388,256 5,218 AUGE–FONASA study
Stroke follow-up (annual) 1,163,564 1,792 AUGE—FONASA—Delphi
Pneumonia/influenza 179,618 277 AUGE—FONASA
Mild COPD (annual) 191,223 294 Microcosting & OS
Moderate COPD (annual) 422,257 650 Microcosting & OS
Severe COPD (annual) 4,689,113 7,221 AUGE—FONASA–OS
Lung cancer 1st year 16,613,003 25,585 Cost-Effectiveness Study
Lung cancer 2nd year 21,480,916 33,082 CE Study & Delphi
Mouth cancer 1st year 11,961,362 18,421 Costing based on the proportions to lung cancer, as found in Delphi exercise in Argentina
Mouth cancer - 2nd year onwards 8,162,748 12,571
Esophageal cancer 1st year 13,954,922 21,491
Esophageal cancer - 2nd year onwards 9,451,603 14,556
Stomach cancer 1st year 13,622,662 20,980
Stomach cancer - 2nd year onwards 10,310,840 15,879
Pancreatic cancer 1st year 11,296,842 17,398
Pancreatic cancer - 2nd year onwards 7,733,130 11,909
Kidney cancer 1st year 11,961,362 18,421
Kidney cancer - 2nd year onwards 8,377,557 12,902
Laryngeal cancer 1st year 13,622,662 20,980
Laryngeal cancer - 2nd year onwards 9,881,221 15,218
Leukemia 1st year 17,942,043 27,632
Leukemia - 2nd year onwards 20,621,679 31,758
Bladder cancer 1st year 11,296,842 17,398
Bladder cancer - 2nd year onwards 10,310,840 15,879
Cervical cancer 1st year 10,300,062 15,863
Cervical cancer - 2nd year onwards 5,578,040 8,590
AUGE: national program of explicit guaranties in health, COPD: chronic obstructive pulmonary disease, CHD: coronary heart disease, FONASA: National Health
Fund, OS: Other sources
�Exchange rate per dollar is the 2017 observed mean value, published by the Chilean Central Bank: 649,33 CLP.
https://doi.org/10.1371/journal.pone.0237967.t003
PLOS ONE The burden of smoking in Chile
PLOS ONE | https://doi.org/10.1371/journal.pone.0237967 August 28, 2020 7 / 16
followed by the group of nine other cancers (17.8%), and the cardiovascular disease group
(13.3%).
In terms of smoking-attributable morbidity, considering that these events are heteroge-
neous for comparison, COPD holds the top place with 55,209 events (65% of the total), fol-
lowed by AMI (13.4%), stroke (5.6%), pneumonia/influenza (5.1%), and lung cancer (4.4%).
Finally, the economic burden for the healthcare system attributed to smoking is distributed
among COPD (28%), the group of nine other cancers (21.1%), lung cancer (19.4%), cardiovas-
cular diseases (14.8%), and passive smoking (11.5%).
DALYs (premature mortality and disability)
Smoking causes a total of 416,445 DALYs (undiscounted and not age-weighted). Of these,
DALYs due to premature mortality account for 69% of total, while the rest is due to disability.
The DALY burden falls mainly on men (59%). Table 6 shows the distribution of DALYs by sex
and disease group for the entire cohort analyzed, as well as the mean differential DALY for
smokers and ex-smokers (in relation to never-smokers), when simulating a cohort of 35 years
of age by its survival time.
Costs, taxes and expenditure on health
Smoking generates a direct annual treatment cost of CLP 1.15 trillion (approx. U$D 1.8 bil-
lion), which is equivalent to 0.6% of the Chilean GDP in 2017, and 8.1% of the country’s
annual healthcare spending. The tax collection on cigarettes sales (and other tobacco products)
was around CLP 979 billion in 2017 [31], an amount that covers 85.3% of the direct expenses
in the health system caused by smoking. Table 7 shows that increases in the final price of a cig-
arettes pack through different tax increases, would allow, in a ten-year period, for further
Table 4. Utilities values used in the model.
Disease health state Utility Source
Acute myocardial infarction (AMI) 0,800 [32]
Non-AMI ischemic event 0,800 [33]
Coronary heart disease (CHD) 0,939 [33]
Stroke 0,641 [32]
Stroke follow-up (annual) 0,740 [34]
Pneumonia/influenza 0,994 [35, 36]
Mild COPD (annual) 0,935 [32]
Moderate COPD (annual) 0,776 [37]
Severe COPD (annual) 0,689 [37]
Lung cancer 0,500 [38]
Esophageal cancer 0,630 [39, 40]
Stomach cancer 0,550 [41]
Pancreatic cancer 0,550 [42]
Kidney cancer 0,780 [43]
Laryngeal cancer 0,890 [44]
Leukemia 0,800 [45, 46]
Bladder cancer 0,780 [43]
Cervical cancer 0,940 [47]
AMI: acute myocardial infarction, COPD: chronic obstructive pulmonary disease, CHD: coronary heart disease.
https://doi.org/10.1371/journal.pone.0237967.t004
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Table 5. Smoking-attributable deaths, events, and directs costs for the healthcare system for 2017.
Tobacco-related conditions Total deaths Smoking- attributable
deaths






n % row % col n % row % col CLP U$D� CLP U$D� % row % col
Cardiovascular diseases 12 948 2 220 17 13.3 37 578 11 386 30 13.4 561 646 865 170 045 262 30 14.8
Acute myocardial infarction 6 248 1 304 21 7.8 37 439 11 330 30 13.3
Non-AMI ischemic event 3 1 20 0.0 139 56 40 0.1
CV death of non-ischemic cause 6 696 916 14 5.5 NA NA NA NA
Stroke 6 356 923 15 5.5 28 666 4 761 17 5.6 322 410 497 57 649 88. 8 18 5.0
Lung cancer 3 673 3 076 84 18.4 4 409 3 712 84 4.4 262 309 404 222 488 342. 6 85 19.4
Pneumonia/influenza 3 198 573 18 3.4 18 675 4 352 23 5.1 3 354 5 782 1. 2 23 0.1
COPD 6 400 5 041 79 30.1 75 528 55 209 73 65.1 413 046 636 321 525 495. 2 78 28.0
Other cancers 8821 1926 34 17.8 14 784 5 401 37 6.4 632 369 974 242 435 373.0 38 21.1
Mouth and pharyngeal cancer 353 246 70 1.5 997 695 70 0.8
Esophageal cancer 861 590 69 3.5 1 152 795 69 0.9
Stomach cancer 2 145 517 24 3.1 2 853 693 24 0.8
Pancreatic cancer 2 121 562 26 3.4 2 378 631 27 0.7
Kidney cancer 837 240 29 1.4 1 813 543 30 0.6
Laryngeal cancer 370 310 84 1.9 804 677 84 0.8
Leukemia 977 176 18 1.1 1 166 216 19 0.3
Bladder cancer 591 259 44 1.5 2 058 916 44 1.1
Cervical cancer 566 83 15 0.5 1 563 236 15 0.3
Second-hand smoking (SHS) and other causes
SHS and other causes 1 926 1 926 100 11.5 NA NA NA NA NA NA 131 940 203.0 100 11.5
Total 43 322 16 742 39 100.0 179 640 84 821 47 100.0 2195 134 3 381 1146 863 1 766 52 100.0
AMI: acute myocardial infarction, CLP: Chilean pesos, COPD: chronic obstructive pulmonary disease, CV: cardiovascular, NA: not applicable, U$D: US dollars
� Exchange rate per dollar 1 U$D = 649,33 CLP.
https://doi.org/10.1371/journal.pone.0237967.t005
Table 6. Years of life lost due to premature mortality and years of disability– 2017.
Disability-adjusted life-years (DALY) Women Men Total %
DALYS due to premature mortality (YLL) 114,227 173,164 287,392 69,0%
DALYS due to disability (YLD) 57,424 71,628 129,052 31,0%
Total DALY 171,652 244,792 416,444 100%
Years of Life Lost (YLL) by disease group
Cardiovascular disease 10,216 26,549 36,765 12.8%
Stroke 8,029 10,179 18,207 6.3%
Pneumonia /influenza 2,065 4,029 6,095 2.1%
COPD 42,561 37,314 79,875 27.8%
Lung cancer 20,883 36,093 56,976 19.8%
Other cancers 17,332 39,079 56,411 19.6%
Passive smoking /other causes 13,141 19,922 33,063 11.5%
Total DALY (YLL) 114,227 173,164 287,392 100.0%
Differential DALY per person in relation to a never-smoker
Smoking status Women Men
Smoker -5.9 -6.1
Ex- smoker -2.6 -2.9
COPD: chronic obstructive pulmonary disease, DALY: disability-adjusted life-years, YLL: years of life lost (YLL), YLD: years of life with disability
https://doi.org/10.1371/journal.pone.0237967.t006
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reductions in deaths, health events, and DALYs, a fact which also comes with significant sav-
ings on treatment costs and higher tax revenue collection.
As can be seen from the table, a 50% increase in the final price of a cigarette package could
prevent 13,665 deaths, 11,955 heart diseases, 7,786 new cancers and 7,607 strokes in ten years.
In addition, financial resources could be generated for around U$D 4.6 billion, a figure that is
derived from savings in health expenses (U$D 1.5 billion) and increase tax collection for ciga-
rettes consumption (U$D 3.1 billion).
Discussion
This analysis shows that Chile faces an important burden associated with the habit of smoking.
Annually, 16,742 deaths, 11,386 cases of AMI and other cardiovascular events, 4,761 strokes
and 9,113 new cancer cases are attributable to smoking. A current smoker of 35 years of age is
expected to lose around six years of disability-adjusted life, and an ex-smoker around 3 years
in their lifespan, due to smoking. The health care system spends around U$D 1.8 billion per
year in direct costs of care of smoking-attributable diseases, which represents 8.1% of the total
health care budget. Despite the latest increases in cigarette taxes, revenues do not fully com-
pensate for the healthcare system costs. We estimate that a further increase in cigarettes taxes
that could drive-up the final price of the pack by 50% would have important accumulated ben-
efits within the next 10 years, such as better health, healthcare savings, and further tax revenue
collection. In Chile, tax increases should affect the specific tax component expressed in UTM,
Table 7. Economic consequences of smoking and potential effects of price increase– 2017.
Category CLP (millions) U$D (millions) Source
Total health expenditure (THE) 14,220,119 21,900 WDI, WB
Gross domestic product (GDP) 180,211,290 277,534 WDI, WB
Tobacco-tax collection 978,696 1,507
Smoking-attributable direct costs of treatment 1,146,863 1,766 [31]
Treatment costs as % of GDP 0.64%
Treatment costs as % of THE 8.07%
% of costs recovered with taxes 85.34%
Scenarios for price increase: 10 years effect for different % increase
% increase in final price of a package 25% 50% 75%
Deaths prevented 6,833 13,665 20,498
Heart disease avoided 5,977 11,955 17,932
Number of Strokes avoided 3,804 7,607 11,411
New cases of cancer avoided 3,893 7,786 11,679
New cases of COPD avoided 17,248 34,496 51,743
DALYs avoided 180,238 360,476 540,713
Health costs avoided (millions of CLP) 471,252 942,504 1,413,756
Increase in tax collection (millions of CLP) 1,335,276 2,052,895 2,152,860
Total economic benefit (millions of CLP) 1,806,528 2,995,399 3,566,616
Health costs avoided (millions of U$D) 726 1,452 2,177
Increase in tax collection (millions of U$D) 2,056 3,162 3,316
Total economic benefit (millions of U$D) 2,782 4,613 5,493
CLP: Chilean pesos, DALY: disability-adjusted life-years, GDP: gross domestic product, THE: total health expenditure, U$D: US dollars, WB: World Bank, WDI: World
Development Indicators
https://doi.org/10.1371/journal.pone.0237967.t007
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which does not depend on the production cost; this way one could avoid manufacturers’ well-
known practice of reducing the net price to minimize tax burden.
Compared to the Burden of Disease Study commissioned by the MoH in 2008 [5], where
the total annual DALY attributed to smoking was 61,093, our results are far above with
416,444 DALYs in 2017. However, we need to consider the time passed, epidemiological and
demographic changes and various differences in methods: for example, passive smoking was
not considered, a high discount rate was used (8%), and age was adjusted for in DALY calcula-
tion [5].
Our results do not differ much from those published in 2014, when 16,532 smoking-attrib-
utable deaths were estimated, equivalent to 18.5% of the country’s annual deaths. DALY, on
the other hand, had been estimated at 428,588–3% more than the current study [22]. In a simi-
lar study, Perú estimated 396,069 smoking-attributable DALY for 2015 with an associated
health expenditure that represented 5.3% of GDP and 61% of the overall public health expendi-
ture [19].
Strong tax policies on tobacco are still not widely used in the region. Among its neighboring
countries, Chile has a higher proportion of smoking-related health expenditure recovered by
tobacco taxation revenues, reaching 85% in this analysis. Peru only collects 9% [19], Colombia
10% [25], Paraguay 20% [20], Brazil 25% [48] and Argentina 67% [18] of total smoking-attrib-
utable healthcare expenditure, through tobacco-taxes.
As percentage of GDP, Peru faces the highest burden in healthcare expenditure with a 5.3%
[19], followed—far behind—by Argentina 0.75% [18], Chile 0.64% (this study), Colombia
0.59% [25] and Brazil 0.5% in 2011 [48].
In this analysis, we found that the impact of a 50% increase in the price of a pack of ciga-
rettes would be a reduction of 13,655 deaths over ten years, a value that is less than our previ-
ous estimates of 20,502 deaths prevented in ten years [49]. However, this previous analysis
used data for 2015 when there was a higher smoking prevalence. As pointed out before, the
national smoking prevalence fell 6.5 percentage points in the 2017 NHS in relation to the 2010
NHS [2, 50], which can be the result of the regulations that have considerably limited the
spaces were smoking is now permitted in Chile. These regulations were enforced with active
supervision and control, and monetary fines were imposed to offenders [51].
The main strengths of this study are that the analysis uses a model platform that has been
widely validated to assess tobacco burden in various Latin American countries [17–21, 24],
and that it incorporates the most updated information available. The latter includes smoking
prevalence, mortality data, and the country population structure presented in the 2017
national census. In this way, this study provides a relevant source for policy guidance. In Chile,
this is the first attempt to assess the economic and healthcare burden of tobacco consumption
comprehensively.
Some of the potential weaknesses of the analysis are that indirect or productivity costs were
not modeled, and that treatment costs were not re-analyzed but only updated to 2017 values,
according to the consumer price index. Furthermore, while smoking is harmful in different
ways, it entails various uncertain externalities, which make it difficult to assess the loss of pro-
ductivity and other indirect costs at country-level appropriately. The study in Brazil shows that
indirect costs can represent 30% of total smoking-attributable costs [21]. Our direct estima-
tions fall short from representing the total smoking burden, which, ideally, should consider all
the negative effects of smoking on people, their families, and society.
The second possible weakness of our study could be related to the cost structure of certain
treatments that might have changed, as new pharmaceutical therapies come to the market
every day. As new drugs are slowly incorporated in programs like AUGE, it is essential to
review current treatments covered by AUGE, since omitting such review may lead to
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underestimation of costs; however, part of this underestimation can be compensated by other
previously included expensive drugs, whose patents have already expired.
Regarding indirect costs, we did not consider smoking on pregnancy; a study using popula-
tion-attributable fractions (PAFs) reported the negative impact of prenatal smoking on infant
morbidity and mortality in Chile for the period 2008–2012 [52]. Using PAFs, the study esti-
mated that between 5.5% and 12.3% of pre-term births (depending on cut-off point) and
27.4% of full-term low-weight births were attributable to prenatal smoking. Additionally,
11.9% of deaths caused by preterm-related causes, and 40% of deaths caused by sudden infant
death syndrome were attributed to prenatal smoking.
The results published in the first report of this analysis in 2014 [22] played a key role as
input information in the discussion of several policies and legislative changes regarding
tobacco control in Chile. On the other hand, many of the regulations implemented since 2013
have already proven effective, even for this short time span. The 2017 NHS shows that people
from all age strata experienced a reduction in their smoking, including those with less than
eight years of schooling. There was also a reduction in the proportion of smokers with high
tobacco dependence (those smoking within the first 60 minutes of waking up in the morning),
which decreased from 33.2% (2010 NHS) to 22.3% (2017 NHS). Passive smokers prevalence
fell from 31.0% to 15.2% during the same period [50].
A 2017 study [53] reported how the number of AMI declined immediately after smoking in
public places was banned. In this analysis, the observed incidence of AMI showed an
OR = 0.60 when comparing the first 30-month post law enforcement, against the 30-month
prior to implementation. This study covered the main urban areas of the country [53].
Despite the recent progress regulating smoking in Chile, the implementation of free-of-
charge cessation assistance programs is lacking. This pending task constitutes a moral impera-
tive as limiting spaces (enclosed and open) to smoke together with increasing cigarettes prices
lead to health and economic vulnerability, especially for those highly-dependent on tobacco
use. The lack of coverage of these services, despite ample evidence on their cost-effectiveness
[54], has been repeatedly pointed out by WHO reports that give account of country compli-
ance of the MPOWER strategy [3, 10, 12]. A 2017 study shows how countries with less national
income than Chile offer better coverage for smoking-cessation services [55].
Public policies should also address smoking by young women who are likely to be mothers
in the future, to avoid the unacceptably high burden that this habit generates for newborns
[52]. This seems even more relevant if we consider that there are far more adolescent females
who are smoking than adolescent males in Chile [3].
Finally, policy-makers need to consider the possible regressive nature of tobacco taxes. A
recent study [13] that analyzed expenditure patterns in Chilean household budgets found that
those who spend more on tobacco, spend less on education and health, especially if they belong
to lower socioeconomic groups.
In conclusion, sustained efforts and political will are necessary to deepen regulations and
widen policy scope. We expect that this study will help raise awareness among government
officials, policy makers, and other relevant stakeholders, about the negative public health and
economic effects of smoking. At the same time, and despite the potential shortcomings of the
study, we expect to have provided insight into appropriate policy options to continue tackling
this problem.
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